Session 16
Antivirals II

Programme

• 02:00 p.m. – 02:15 p.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 45

  Discovery of host-targeting broad-spectrum antiviral agents by using advanced virtual screening

  • Hovakim Zakaryan (Yerevan / AM)

   Antivirals, Virus-host interactions: entry, replication, assembly, egress
• 02:15 p.m. – 02:30 p.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 46

  The human serine protease inhibitor SerpinB3 and recombinant variants can target Cathepsin L, TMPRSS2 and Furin and can inhibit SARS-CoV-2 Cell Entry and Replication

  • Dr. Margaret Worrall (Dublin / IE)

   Antivirals, SARS -CoV2 and other coronaviruses
• 02:30 p.m. – 02:45 p.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 47

  Bicycles – an antiviral modality based on multivalent bicyclic peptides delivers potent SARS-CoV-2 therapeutics

  • Dr. Anna Albecka-Moreau (Cambridge / GB)

   Antivirals, SARS -CoV2 and other coronaviruses
• 02:45 p.m. – 03:00 p.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 48

  Monocarboxylate transporters as novel anti-adenoviral targets

  • Professor Mikael Elofsson (Umeå / SE)

   Antivirals, Virus-host interactions: entry, replication, assembly, egress
• 03:00 p.m. – 03:15 p.m. 10 Min. 5 Min.

  • Abstract Talk
  • AT 49

  A comprehensive study of SARS-CoV-2 main protease mutations generated in a safe, non-gain-of-function, VSV-based system

  • Emmanuel Heilmann (Innsbruck / AT)

   Antivirals, SARS -CoV2 and other coronaviruses